Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Corcept Therapeutics (CORT – Research Report), Incyte (INCY – Research Report) and Nkarta (NKTX – Research Report).
Incyte (INCY)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Incyte on January 9. The company’s shares closed last Wednesday at $64.14.
According to TipRanks.com, Berens is a 1-star analyst with an average return of
Currently, the analyst consensus on Incyte is a Moderate Buy with an average price target of $75.29, implying a 17.3% upside from current levels. In a report issued on January 2, Citi also maintained a Buy rating on the stock with a $82.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CORT:
- Corcept Therapeutics announces $200M stock buyback
- Corcept Therapeutics guides FY24 revenue at $600M-$630M, consensus $513.9M
- Corcept Therapeutics sees Q4 revenue at $135.4M, consnesus $127.9M
- Biotech Alert: Searches spiking for these stocks today
- Corcept Therapeutics price target lowered to $28 from $34 at H.C. Wainwright
